Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential
participant.
The goal of this clinical research study is to find the highest tolerable dose of gemcitabine
that can be given by inhalation (breathing it as a mist) to patients with solid tumors that
have spread to the lungs from other parts of the body.
The safety and side effects of this drug will also be studied.
This is an investigational study. Gemcitabine is FDA approved and commercially available for
the treatment of pancreatic and lung cancer, and other solid tumors. Its administration by
inhalation is investigational. The study doctor can explain how the study drug is designed to
work.
Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Gateway for Cancer Research James B. and Lois R. Archer Charitable Foundation